longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Neurocrine Biosciences

NBIX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 22.51, below the reasonable range, cheaper than 93.25% of the time in the past 5 years, and the industry ranks 41/601, the industry Median -2.50.

22.51xP/E
$156.22Stock price
$6.94Earnings per share
22.51xP/E
Stock price$156.22Earnings per share$6.94

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
41.48x
Typical range
31.26x–101.10x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
AMGNUSAmgen
23.33x11.10%$204.01B
VRTXUSVertex Pharma
29.66x36.49%$130.64B
REGNUSRegeneron Pharma
18.59x4.10%$80.46B
INCYUSIncyte
15.27x65.04%$24.62B
UTHRUSUnited Therap
16.26x6.53%$21.32B
GMABUSGenmab A/S
25.34x24.93%$19.97B
ASNDUSAscendis Pharmac
20.13x482.14%$17.33B
NBIXUSNeurocrine Biosciences
22.51x50.66%$15.88B
EXELUSExelixis
16.16x16.46%$13.91B
HALOUSHalozyme Therap
29.42x181.51%$12.17B
TGTXUSTG Therap
18.68x65.83%$8.25B
VCYTUSVeracyte
28.70x35.19%$3.29B
CDNAUSCaredex
23.42x629.58%$2.60B
MGTXUSMeiraGTx
15.55x122.03%$1.23B
PBYIUSPuma BioTech
17.62x37.70%$470.78M
KMDAUSKamada
20.54x39.29%$457.07M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.